Insights
Insights From Our Experts
Articles
Real-World Insights: Effectiveness and Safety of Crizotinib in ROS1-Rearranged NSCLC
Lung cancer is one of the most incident malignancies and the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and, with the emergence of genomic techniques,…
Demystifying the New Prescription Drug Use-Related Software Framework
Authors: Kory Dillman and Scott Kellogg The Food and Drug Administration (FDA) unveiled its draft guidance on Regulatory Considerations for Prescription Drug Use-Related Software (PDURS) in September 2023. The document shed light on how the FDA intended…
Price Right or Pay Later
Dive into the intricate world of pharmaceutical pricing with “Price Right or Pay Later” by Chad McAuliffe, and Andrew Therrien. In this groundbreaking paper, EVERSANA exposes the critical yet often overlooked nuances of pricing strategies in…
Leveraging Generative AI in Brand Planning: Insights from Second Annual Pharmaceutical Brand Planning Survey
Discover the cutting-edge insights from EVERSANA’s second annual Pharmaceutical Brand Planning Survey. Dive into the burgeoning trend of integrating generative AI into brand planning within the life sciences sector. This comprehensive report, based on responses from…
Maximizing Sales Impact in a Hybrid World
In an evolving pharmaceutical landscape, traditional sales methods are giving way to a new hybrid approach. “Maximizing Sales Impact in a Hybrid World” delves into this transformative shift, exploring how data-driven strategies blend personal and non-personal…
Equip FRMs with the Right Tools to Unlock Patient Access
In the modern healthcare landscape, multiple daunting challenges muddy pharmaceutical manufacturers’ ability to ensure patients have timely and uncomplicated access to high-quality care and life-altering medications. A plethora of obstacles can impede the processes of finding…
Unveiling Challenges: Analyzing Stakeholder Feedback on the EU Joint Clinical Assessment Implementation Act and Its Impact on the Latest Draft
On March 5, 2024, the draft Implementation Act (IA) for Joint Clinical Assessment (JCA) for medicinal products was released for public comments. The intent of the draft IA was to provide more granular details on the…
Transforming Systematic Literature Reviews: Leveraging AI for Efficiency and Rigor
Systematic literature reviews (SLRs) are instrumental in supporting healthcare decision-making and market access. Traditionally, literature reviews require a resource-intensive process, thus highlighting the need for more efficient methodologies without compromising rigor or integrity. Over the past…
Decoding EMA’s Blueprint on Real-World Evidence
The European Medicines Agency (EMA) has published a document that elaborates on the application of Real-World Data (RWD) in evaluating human medicines. This document succinctly outlines the utility of Real-World Evidence (RWE), which is derived from…
Predicting Telehealth Use through the Power of Machine Learning: Insights from EVERSANA to Be Shared at Upcoming PMSA Conference.
Telehealth has emerged as a vital channel for health services delivery in the post-COVID era. However, understanding patient telehealth use remains a complex challenge for healthcare providers. At EVERSANA, our experts are leveraging machine learning techniques…